Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tremelimumab · 1 trial · 1 indication
The Objective Response Rate (ORR) is defined as the proportion of patients who have either a Partial Response (PR) or a Complete Response (CR) to treatment. CR and PR are the best overall response across all time points of tumor evaluation. Overall tumor response at each time point is assessed according to the modified RECIST criteria for HCC.
| Arm | Type | Description |
|---|---|---|
| Hepatocellular carcinoma with portal vein thrombosis and without hepatic spread | EXPERIMENTAL | Patient will receive selective internal radiation therapy and immunotherapy as per standard of care. SIRT Administration is direct intra-arterial injection in the hepatic artery to target only liver disease and IO will be performed as describe below: * Tremelimumab (Imjudo®): 300 mg IV, one-hour infusion; * Durvalumab (Imfinzi®): 1500 mg IV, one-hour infusion every 4 weeks. |
| Name | Type | Description |
|---|---|---|
| Selective Internal Radiotherapy | DEVICE | SIRT will use Yttrium-90 glass-microspheres (TheraSphereTM). SIRT needs two steps: the treatment simulation (diagnostic angiography and scintigraphy of hepatic perfusion with 99mTc-MAA) and the administration (during a therapeutic angiography). |
| Tremelimumab | DRUG | Tremelimumab should be done 1 to 3 weeks after SIRT and is administrated according to the Summary of Product Characteristic (SPC). |
| Durvalumab | DRUG | After the end of the tremelimumab infusion, patient receive durvalumab then one injection every 4 weeks until further progression upon investigator decision. Also administrated according to the Summary of Product Characteristic (SPC). |
Inclusion Criteria: 1. Age ≥ 18, 2. ECOG Performance Status 0-1, 3. Histologically proven HCC or noninvasive HCC diagnosis according to LiRADS criteria, 4. HCC with Portal vein involvement (PVT), segmental, sectorial or lobar, evaluated by diagnostic imaging (CT scan or MRI), 5. At least one measur...
Tremelimumab is being studied for the treatment of non-resectable hepatocellular carcinoma. It is currently in Phase 2 clinical development for this indication. The drug is being evaluated in combination with selective internal radiation therapy (SIRT) followed by immunotherapy in patients with hepatocellular carcinoma and portal vein thrombosis.
Tremelimumab is a monoclonal antibody, indicated by its -mab suffix. It is being investigated for its role in cancer immunotherapy, specifically in the treatment of non-resectable hepatocellular carcinoma. The drug is part of an ongoing Phase 2 clinical trial evaluating its efficacy in this patient population.
Boston Scientific Corporation (ticker: BSX) is developing Tremelimumab. The company is conducting a Phase 2 clinical trial of the drug for the treatment of non-resectable hepatocellular carcinoma. The trial is currently recruiting participants in France.
Tremelimumab is in Phase 2 clinical development. It is being studied as an investigational treatment for non-resectable hepatocellular carcinoma. The drug has not been approved by regulatory authorities and remains in active clinical investigation.
Tremelimumab is being evaluated in a Phase 2 clinical trial with the identifier NCT07122089. The trial is titled 'Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis' and is recruiting 80 participants in France. The study is currently in the recruiting stage.
Tremelimumab is a distinct investigational monoclonal antibody being developed by Boston Scientific Corporation. It is being studied specifically for non-resectable hepatocellular carcinoma. No alternative names for this drug have been established in the clinical trial information available.